Matteo Caridi, Marika Alborghetti, Valeria Pellicelli, Rosamaria Orlando, Francesco Ernesto Pontieri, Giuseppe Battaglia, Antonietta Arcella
{"title":"神经传导型 \"胶质母细胞瘤的3型和5型代谢谷氨酸受体特征：一种生物信息学方法。","authors":"Matteo Caridi, Marika Alborghetti, Valeria Pellicelli, Rosamaria Orlando, Francesco Ernesto Pontieri, Giuseppe Battaglia, Antonietta Arcella","doi":"10.2174/1570159X22666240320112926","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma (GBM) represents an aggressive and common tumor of the central nervous system. The prognosis of GBM is poor, and despite a refined genetic and molecular characterization, pharmacological treatment is largely suboptimal.</p><p><strong>Objective: </strong>Contribute to defining a therapeutic line in GBM targeting the mGlu3 receptor in line with the principles of precision medicine.</p><p><strong>Methods: </strong>Here, we performed a computational analysis focused on the expression of type 3 and 5 metabotropic glutamate receptor subtypes (mGlu3 and mGlu5, respectively) in high- and low-grade gliomas.</p><p><strong>Results: </strong>The analysis allowed the identification of a particular high-grade glioma type, characterized by a high expression level of both receptor subtypes and by other markers of excitatory and inhibitory neurotransmission. This so-called neurotransmitter-GBM (NT-GBM) also shows a distinct immunological, metabolic, and vascularization gene signature.</p><p><strong>Conclusion: </strong>Our findings might lay the groundwork for a targeted therapy to be specifically applied to this putative novel type of GBM.</p>","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":" ","pages":"1923-1939"},"PeriodicalIF":4.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284726/pdf/","citationCount":"0","resultStr":"{\"title\":\"Metabotropic Glutamate Receptors Type 3 and 5 Feature the \\\"NeuroTransmitter-type\\\" of Glioblastoma: A Bioinformatic Approach.\",\"authors\":\"Matteo Caridi, Marika Alborghetti, Valeria Pellicelli, Rosamaria Orlando, Francesco Ernesto Pontieri, Giuseppe Battaglia, Antonietta Arcella\",\"doi\":\"10.2174/1570159X22666240320112926\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Glioblastoma (GBM) represents an aggressive and common tumor of the central nervous system. The prognosis of GBM is poor, and despite a refined genetic and molecular characterization, pharmacological treatment is largely suboptimal.</p><p><strong>Objective: </strong>Contribute to defining a therapeutic line in GBM targeting the mGlu3 receptor in line with the principles of precision medicine.</p><p><strong>Methods: </strong>Here, we performed a computational analysis focused on the expression of type 3 and 5 metabotropic glutamate receptor subtypes (mGlu3 and mGlu5, respectively) in high- and low-grade gliomas.</p><p><strong>Results: </strong>The analysis allowed the identification of a particular high-grade glioma type, characterized by a high expression level of both receptor subtypes and by other markers of excitatory and inhibitory neurotransmission. This so-called neurotransmitter-GBM (NT-GBM) also shows a distinct immunological, metabolic, and vascularization gene signature.</p><p><strong>Conclusion: </strong>Our findings might lay the groundwork for a targeted therapy to be specifically applied to this putative novel type of GBM.</p>\",\"PeriodicalId\":10905,\"journal\":{\"name\":\"Current Neuropharmacology\",\"volume\":\" \",\"pages\":\"1923-1939\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284726/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Neuropharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/1570159X22666240320112926\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1570159X22666240320112926","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Metabotropic Glutamate Receptors Type 3 and 5 Feature the "NeuroTransmitter-type" of Glioblastoma: A Bioinformatic Approach.
Background: Glioblastoma (GBM) represents an aggressive and common tumor of the central nervous system. The prognosis of GBM is poor, and despite a refined genetic and molecular characterization, pharmacological treatment is largely suboptimal.
Objective: Contribute to defining a therapeutic line in GBM targeting the mGlu3 receptor in line with the principles of precision medicine.
Methods: Here, we performed a computational analysis focused on the expression of type 3 and 5 metabotropic glutamate receptor subtypes (mGlu3 and mGlu5, respectively) in high- and low-grade gliomas.
Results: The analysis allowed the identification of a particular high-grade glioma type, characterized by a high expression level of both receptor subtypes and by other markers of excitatory and inhibitory neurotransmission. This so-called neurotransmitter-GBM (NT-GBM) also shows a distinct immunological, metabolic, and vascularization gene signature.
Conclusion: Our findings might lay the groundwork for a targeted therapy to be specifically applied to this putative novel type of GBM.
期刊介绍：
Current Neuropharmacology aims to provide current, comprehensive/mini reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience.
The journal serves as a comprehensive, multidisciplinary expert forum for neuropharmacologists and neuroscientists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
